Tyenne®, the first approved tocilizumab biosimilar in the UE
Tyenne® Marks the debut of the first Tocilizumab biosimilar in the European Union
Fresenius Kabi has unveiled its tocilizumab biosimilar, Tyenne®, in the European Union, offering a pivotal breakthrough in providing an accessible, cost-effective, high-quality, and secure treatment option for European patients undergoing tocilizumab therapy. This milestone establishes Tyenne® as Fresenius Kabi’s third approved biosimilar in Europe, and it can be administered via both subcutaneous and intravenous methods.
The company’s expanding portfolio of biosimilars, dedicated to addressing inflammatory and immune diseases as well as oncology treatments, underscores its Vision 2026 growth strategy.
Fresenius Kabi, a global healthcare company specializing in biopharmaceuticals, clinical nutrition, medical technologies, and intravenous generic drugs for critical and chronic conditions, has officially introduced its tocilizumab biosimilar, Tyenne®, in the European Union. This biosimilar product represents a reference to RoActemra® (tocilizumab).
Tyenne® emerges as the first tocilizumab biosimilar available in Europe for treating various inflammatory and immune diseases, encompassing conditions such as rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, cytokine release syndrome (CRS), and also for the treatment of COVID-19.
Tyenne® stands as Fresenius Kabi’s third approved biosimilar, extending a versatile range of user-friendly administration options, including subcutaneous (prefilled syringe and autoinjector) and intravenous (vials) methods. Backed by Fresenius Kabi’s comprehensive support program for healthcare professionals (HCPs) and patients, this biologic medicine broadens treatment possibilities and contributes to the sustainable functioning of healthcare systems in Europe.
Pierluigi Antonelli, CEO of Fresenius Kabi, emphasized, “Today’s launch is a testament to our Vision 2026 growth strategy, aimed at providing essential treatment options for patients and healthcare professionals worldwide. The introduction of tocilizumab in the European market bolsters our path of expansion, enriching our biopharma portfolio with cutting-edge medicines. Being the pioneer in offering a tocilizumab biosimilar in the EU demonstrates our ambition to lead in the biopharma segment.”
Dr. Michael Schönhofen, President of Fresenius Kabi Biopharmaceuticals, added, “We take great pride in being the first company to offer an affordable, high-quality, safe, and alternative tocilizumab treatment for healthcare providers and patients dealing with inflammatory and immune diseases. With both subcutaneous and intravenous administration options, we believe that Tyenne® will revolutionize the treatment landscape, improve patient outcomes, and alleviate financial burdens on patients and healthcare systems. Our commitment to patient well-being and healthcare advancement aligns with our continual expansion of the immunology and oncology portfolio, establishing us as a dependable partner in the biopharmaceutical space.”
In addition to its two available biosimilars, Idacio® (adalimumab) and Stimufend® (pegfilgrastrim), Fresenius Kabi is actively advancing its pipeline of autoimmune and oncology biosimilars, with multiple molecules in late-stage development.
About Tyenne®, a Tocilizumab Biosimilar: Tyenne® (tocilizumab) is a biosimilar to the reference medicinal product RoActemra®, an Interleukin-6 (IL-6) receptor antagonist. Tocilizumab is a biological therapy approved in the EU for various inflammatory and immune-mediated conditions, encompassing rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, cytokine release syndrome (CRS), and the treatment of COVID-19.
Tyenne® underscores Fresenius Kabi’s dedication to expanding access to affordable and cost-effective biosimilars for patients worldwide while offering savings to healthcare systems. KabiCare, Fresenius Kabi’s comprehensive patient support program, is available to patients and healthcare providers from the European launch date.